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Hemophilia B is a classical monogenic, X-chromosomal, recessivelytransmitted bleeding disorder caused by genetic variants within thecoagulation factor IX gene (F9). Although hemophilia B has been
described in dogs, it has not yet been reported in the Hovawart breed. Here
we describe the identification of a Hovawart family transmitting typical
signs of an X-linked bleeding disorder. Five males were reported to suffer
from recurrent hemorrhagic episodes. A blood sample from one of these
males with only 2% of the normal concentration of plasma factor IX
together with samples from seven relatives were provided. Next-generation
sequencing of the mother and grandmother revealed a single nucleotide
deletion in the F9 promoter. Genotyping of the deletion in 1,298 dog spec-
imens including 720 Hovawarts revealed that the mutant allele was only
present in the aforementioned Hovawart family. The deletion is located 73
bp upstream of the F9 start codon in the conserved overlapping DNA bind-
ing sites of hepatocyte nuclear factor 4α (HNF-4α) and androgen receptor
(AR). The deletion only abolished binding of HNF-4α, while AR binding
was unaffected as demonstrated by electrophoretic mobility shift assay
using human HNF-4α and AR with double-stranded DNA probes encom-
passing the mutant promoter region. Luciferase reporter assays using wild-
type and mutated promoter fragment constructs transfected into Hep G2
cells showed a significant reduction in expression from the mutant promot-
er. The data provide evidence that the deletion in the Hovawart family
caused a rare type of hemophilia B resembling human hemophilia B
Leyden.
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ABSTRACT
Introduction
Hemophilia B (Christmas disease) is a recessive, X-linked bleeding disorder
caused by genetic variants within the clotting factor IX gene (F9) resulting in the
absence or insufficient levels of factor IX (FIX) in the blood.1 In humans hemophilia
B is also known as the “royal disease” as it was transmitted into several European
royal dynasties by Queen Victoria.2,3 As of present, 1,113 unique F9 variants have
been described in humans.4 The majority of the pathogenic variants are located
within exons (n=923) and intronic regions (n=137) of F9. Only 33 variants (2.96%)
have been described in the 5’-UTR (n=28) and 3’-UTR (n=5) accounting for 2.52%
and 0.45% of human pathogenic hemophilia B variants, respectively.4
Although the first reports about canine hemophilia B date back to the early 1960s
and this was the first disorder in dogs characterized on the
DNA level, data on hemophilia B cases in dogs remain
rather scarce compared to data from humans.5-8 For
instance, in the Cairn Terrier colony of the Francis Owen
Blood Research Laboratory (University of North Carolina,
Chapel Hill, NC, USA) a G>A transition
(NC_006621.3:g.109,532,018G>A) in exon 8 causing an
amino acid exchange (NP_001003323.1:p.Gly418Glu) that
resulted in a complete lack of circulating FIX was detected
in affected dogs.9 Due to a complete deletion of F9 in a
Labrador Retriever, FIX inhibitors were produced after
transfusion of canine blood products.10 In a study of Pit
Bull Terrier mixed breed dogs and Airedale Terrier dogs a
large deletion of the entire 5’ region of F9 extending to
exon 6 was found in the former and a 5 kb insertion dis-
rupting exon 8 was described in the latter.11 As in the
Labrador Retriever with hemophilia B, FIX inhibitors were
produced in both breeds. A mild form of hemophilia B in
German Wirehaired Pointers was caused by a 1.5 kb Line-
1 insertion in intron 5 of F9 at position
NC_006621.3:g.109,521,130.12 Until today, hemophilia B
has been described in four mixed-breed dogs and nine dog
breeds, i.e. German Shepherd, Lhasa Apso, Labrador
Retriever, Rhodesian Ridgeback, Airedale Terrier, Cairn
Terrier, Maltese, Mongrel and German Wirehaired
Pointer.9-17
In the canine cases analyzed so far on the DNA level,
mutations have been observed only in exons and introns
of F9, whereas alterations of the F9 promoter have not
yet been reported. In humans promoter variants have
been detected and result in the so-called hemophilia B
Leyden characterized by low levels of FIX until puberty,
whereas after puberty FIX concentrations rise to almost
normal levels.18-20 Since its first description, the genetic
background of human hemophilia B Leyden was elucidat-
ed by various studies identifying variants in different
transcription factor binding sites in the F9 promoter
including the androgen-responsive element (ARE), hepa-
tocyte nuclear factor 4α (HNF4α), one cut homeobox
(ONECUT1/2) and CCAAT/enhancing-binding protein α
(C/EBPα) binding sites.21,22 HNF4α is a liver-enriched
member of the nuclear receptor superfamily of ligand-
dependent transcription factors and has been associated
with several disorders, including diabetes, atherosclero-
sis, hepatitis, cancer, and hemophilia.23 Promoter analyses
have identified at least 140 genes with HNF4α binding
sites. A recent, more detailed analysis using protein bind-
ing microarrays identified an additional 1,400 potential
binding sites.24,25 Hence, HNF4α plays an important role in
the regulation of numerous genes especially in the main-
tenance of many liver-specific functions. Liver-specific
HNF4α-null mice have been used to study the involve-
ment of hepatic HNF4α in blood coagulation. In the
murine model it was shown that expression of factors V,
XI, XII, and XIIIB depends directly on hepatic HNF4α and
FIX expression was decreased with significantly pro-
longed activated partial thromboplastin time (aPTT).26
Ten of the so far identified 28 5’-UTR variants (35.7%) are
located within the overlapping binding sites of the andro-
gen receptor (AR) and HNF4α in the human F9 promot-
er.4,21 Four variants at positions -21, -20 and -19 only affect
HNF4α binding and all of them have been shown to
cause hemophilia B Leyden.19,27-30 The remaining six vari-
ants at positions -26, -24 and -23, located in the overlap-
ping region, cause the so-called hemophilia B
Brandenburg.31,32 Unlike the classical hemophilia B
Leyden, FIX levels in patients with these variants cannot
be restored by testosterone-driven AR activity and
remain low after puberty with no clinical recovery.21,32
Methods
Animals and genomic DNA isolation
Canine blood and/or hair samples were collected by local vet-
erinarians. The collection of samples was approved by the Lower
Saxony State Office for Consumer Protection and Food Safety
(33.19-42502-05-15A506) according to §8a Abs. 1 Nr. 2 of the
German Animal Protection Law (TierSchG). Blood collected into
EDTA and/or hair samples were provided by different Hovawart
and dog breeders with written consent from the dogs’ owners.
DNA was extracted from 30-50 hair roots using the QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany) according to the man-
ufacturer‘s instructions.33 A salting out procedure was used to
obtain DNA from the EDTA blood samples.34 Additional DNA
samples deposited with the Institute of Veterinary Medicine were
used as controls. All samples were pseudonymized using internal
identities.
Next-generation sequencing and genotyping
DNA from animals #4 and #6 was used for next-generation
sequencing on an Illumina HiSeq2500. The quality of the fastq-
files was analyzed using FastQC 0.11.7.35 Total reads of
1,029,601,630 (#4; sequencing depth 51x) and 1,000,503,256 (#6;
sequencing depth 50x) were obtained and mapped to the refer-
ence canine F9 gene (NC_006621.3, region 109,501,341 to
109,533,798; CanFam3.1) using DNASTAR Lasergene Genomics
Suite SeqMan NGen 15.2.0 (130).36-40
Targeted genotyping of the promoter deletion was done by
polymerase chain reaction (PCR) amplification with primers
cfa_F9_Ex1_F (5’-CCACTGAGGGAGATGGACAC-3’) and
cfa_F9_Ex1_R (5’-CCCACATGCTGACGACTAGA-3’) resulting
in a fragment of 328 bp (wildtype) or 327 bp (deletion) spanning
the variant position. The resulting PCR products were either
directly sequenced on an ABI 3730 Genetic Analyzer (Thermo
Fisher Scientific, Basel, Switzerland) or genotypes were deter-
mined by restriction fragment length polymorphism analysis after
cleavage with RsaI. The wildtype allele generated two fragments
of 52 bp and 276 bp while the allele with the deletion remained
uncut.
Electrophoretic mobility shift assay 
For the electrophoretic mobility shift assay, biotin-labeled, dou-
ble-stranded wildtype (cfa_F9n_wt_Biotin: 5’-CAGAAGTAAAT-
ACAGCTCAACTTGTACTTTGGAACAACTGGTCAACC-3’)
and mutated (cfa_F9n_mut_Biotin: 5’-CCAGAAGTAAAT-
ACAGCTCAACTTGTATTTGGAACAACTGGTCAACC-3’)
oligonucleotides were synthesized (Integrated DNA Technologies
IDT, Leuven, Belgium) harboring the overlapping HNF4α and AR
binding sites (underlined). The position of the deleted C-
nucleotide is indicated in bold and italics. Recombinant human
HNF4α and human AR overexpression lysate were purchased
from Origene Technologies Inc. (Rockville, MD, USA).
DNA was detected using the Chemiluminescent Nucleic Acid
Detection Module Kit (Thermo Scientific, USA) with minor mod-
ifications, i.e. membranes were incubated for 1 min in the sub-
strate working solution.
Luciferase assay
pGL3 Luciferase Reporter Vectors (pGL3-Basic, pGL3-Control)
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were used for the luciferase assay (Promega, Mannheim,
Germany). The wildtype F9 promoter fragment (971 bp wildtype)
was generated by PCR using primers cfa9_HindIII_F_neu (5’-
C G TA G A C T TA G C A C T G T T C AAAGCTTCACACA-
CACAGTTCTTAAAT-3’) and cfa9_HindIII_R_neu (5’-ATGGC-
TAGCAACCGTCTAAGAAGCTTAATTGTGCAAGGAG-
CAAGG-3’). The mutated F9 promoter fragment (970 bp) was
generated by PCR using primers cfa9_HindIII_F (5’-ATCGT-
CAAGCTTCACACACACAGTTCTTAAAT-3’) and
cfa9_HindIII_R (5’-CGTACGAAGCTTAATTGTGCAAGGAG-
CAAGG-3’). For cloning into the HindIII restriction site of pGL3,
primers were designed with an unspecific random 5’-tag (italics)
followed by a HindIII restriction site (underlined) (Online
Supplementary Figure S1). DNA from female carrier #6 served as a
template for amplification. Low expression levels of C/EBP in Hep
G2 cells were complemented by co-transfection of a C/EBPα
expression vector.22 Data are presented as relative response ratios.41
A Mann-Whitney U test was used to determine statistical signifi-
cance. Values were considered statistically significant when
P<0.05 (weakly significant), P<0.01 (medium-strength signifi-
cance) and P<0.001 (strongly significant).
Other methods
Further details of the study methods are given in the Online
Supplementary Appendix.
Results
Hemophilias are rare diseases in dogs and hence it was
rather coincidental that a case in a Hovawart (#3, Figure 1)
was reported to us. With the reconstruction of the pedi-
gree using the online dog breed database and pedigree
data of individual dogs provided by the owners it was
possible to trace the disease back to the female carrier #39
(Figure 1, Online Supplementary Figure S2).42 In the studied
family the hemophilia was transmitted to animals #19, #4
and #6. Bitch #19 had one litter with three hemophilic
males (#48, #51, #53). Bitches #4 and #6 had litters with
one affected male each, #60 and #3, respectively. Although
DNA samples from animals #48, #51, #53 and #60 were
not available, blood parameters and medical reports about
recurrent hemorrhagic episodes were provided (Online
Christmas disease in a Hovawart family
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Figure 1. Pedigree section of the hemo-
philia B Leyden Hovawart family and
DNA sequence comparison of the
mutant hepatocyte nuclear factor
4α/androgen receptor binding site in
the promoter of canine F9 in the hemo-
philic male (#3) and relatives (#4
grandmother, #5 sister, #6 mother, #7
cousin). Pedigree symbols are accord-
ing to the standardized human pedigree
nomenclature.61 Individuals are pseudo-
nymized using internal identities. DNA
samples were available from individuals
indicated with an arrow. DNA
sequences of heterozygous bitches #4
and #6 (female carriers) show overlap-
ping peaks with similar heights 5’ of the
deletion position. For males #48, #51,
#53 and #60, signs of hemophilia
(Online Supplementary Table S1) were
reported and the dogs had to be eutha-
nized after recurrent hemorrhages. Xm:
maternal X chromosome; Xp: paternal X
chromosome; HNF4α: hepatocyte
nuclear factor 4α binding site (consen-
sus sequence: 5’-TGNACTTTG-3’);21,48
AR: 3’-part of the androgen receptor
binding site (consensus sequence: 5’-
AGNACANNNTGTNCT-3’).21,48
Supplementary Table S1). These males had increased aPTT
ratios of 2.93 (#53) to 4.76 (#51) indicative of defects in the
intrinsic coagulation pathway and also reduced FIX con-
centrations in the blood as is normally the case in hemo-
philia B. The affected dog #3 presented only 2% of the
standard FIX concentration. The female carriers #4 and #6
showed aPTT ratios within the reference range. FIX con-
centrations, however, were slightly below the reference
range (#6). This was not surprising as it has been shown
that minute reductions in FIX concentrations might not
always be reflected in an aPTT increase because of the
sensitivity of commercial reagents.43 The clinical signs
together with the blood coagulation parameters and X-
linked transmission supported the diagnosis of hemophil-
ia B. The definite clinical diagnosis prompted us to search
for the molecular cause initially on the DNA level. The
canine F9 gene is located on chromosome X (CFAX)
between positions 109,501,341 (transcription start site)
and 109,533,798 and has a length of 32,458 bp
(NC_006621.3, CanFam3.1). The canine F9 gene, similarly
to that of other mammals, has eight exons with an open
reading frame of 1,356 bp coding for 452 amino acids.44
DNA of female carriers #4 and #6 was subjected to whole
genome sequencing and aligned to the canine reference F9
gene sequence. Surprisingly, only six sequence variants
outside the coding regions of F9 were identified (Table 1).
Five variants were located in introns and were excluded as
the cause of the hemophilia B in the Hovawarts because
these variants were also detected in unaffected controls.
The remaining variant (deletion) was located in the pro-
moter of F9 73 bp upstream of the start codon (Online
Supplementary Figures S1 and S3). As this deletion was
located within a putative transcription factor binding site
of HNF4α and AR, which had been shown in humans to
be important for F9 expression and mutated in hemophilia
B Leyden and Brandenburg,31,32 this position was analyzed
in more detail.
Figure 1 shows the segregation of the nucleotide deletion
in the affected Hovawart family. The female carriers #4
and #6 were heterozygous, as evidenced by the overlap-
ping peaks with similar heights 5’ of the deletion position.
The affected male #3 was hemizygous for the deleted
allele whereas his sister #5 and cousin #7 were homozy-
gous wildtype. Genotyping of 1,298 dogs (including 83 dif-
ferent breeds, 720 unrelated Hovawarts, and 12 Hovawart
family members) demonstrated the occurrence of the dele-
tion only among members of the affected Hovawart family
(Table 2, Online Supplementary Table S2). To provide proof
that the deletion represented the causative genetic variant
and resulted in the low expression of F9, functional analy-
ses using electrophoretic mobility shift and luciferase
reporter assays were performed.
As shown in Figure 2, no binding of recombinant HNF4α
to the mutated promoter region was detected. On the
other hand, the AR lysate clearly showed binding to both
fragments and hence the deletion seems not to influence
AR binding to the androgen-responsive element in the
canine F9 promoter. To analyze the effect of the promoter
variant on F9 expression, wildtype and mutated promoter
fragment luciferase constructs were transfected into Hep
G2 cells. As shown in Figure 3 the mutated promoter frag-
ment resulted in a statistically highly significant (P=2.2x10-
6) reduction of the relative response ratio to approximately
34.6% of the wildtype promoter in the presence of C/EBP
(+ C/EBP). C/EBP is clearly also an important transcription
factor in the regulation of the canine F9 promoter as shown
when C/EBP was not co-transfected (- C/EBP). In the
absence of C/EBP the relative response ratio of the wild-
type promoter was 29.8%. On the other hand there were
no significant differences between the mutated promoter
fragment (+/- C/EBP) and the wildtype promoter fragment
(- C/EBP). As for variants of the HNF4α site, disruption of
the C/EBP binding site has also been shown to be causative
for hemophilia B in humans.45,46
Discussion
As in humans, hemophilia A and B are also rare diseases
in dogs caused by sequence variants in the coagulation
B. Brenig et al.
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Table 1. DNA sequence variants in the canine F9 gene determined by next-generation sequencing of DNA of animals #4 and #6.
Position                          Ref/Alta                              Gene region                                HGVSb g.
X:109501492                              C/-                                     5’-flanking region                                   NC_006621.3:g.109501492delC
X:109504229                              C/-                                              intron 1                                            NC_006621.3:g.109504229delC
X:109505462                             -/AG                                             intron 1                                            NC_006621.3:109505462_109505463insAG
X:109507446                               -/A                                              intron 2                                            NC_006621.3:109507446_109507446insA
X:109510986                              G/A                                              intron 3                                            NC_006621.3:g.109510986G>A
X:109524055                              A/G                                              intron 6                                            NC_006621.3:g.109524055A>G
aRef/Alt: reference nucleotide/alternate nucleotide; bHGVS: Human Genome Variation Society (http://www.hgvs.org).
Table 2. F9 genotype frequencies
                                                                                                    Hovawart                                                                                             Other breedsb
Genotype             HBa affected (n=1)                  HB carrier (n=2)           Control, related (n=12)               Control, unknown              Controls (n= 567)
                                                                                                                                                               relationship (n= 720)                         
C/C                                                                                                                                                     12                                                    720                                             567
C/-                                                                                                    2                                                                                                                                                             
-/-                                               1                                                                                                                                                                                                                    
aHB: hemophilia B; bdog breeds used as controls are listed in Online Supplementary Table S2.
factor VIII (F8) and IX (F9) gene, respectively.47 Since the
1960s cases of canine hemophilia B have been reported
and in 1989 the first description of the molecular cause in
a Cairn Terrier population at the Francis Owen Blood
Research Laboratory was published.5,8,9,44
Since then only six further types of variants, all of them
affecting the coding region of the F9 gene, i.e. deletions,
insertions, missense variants, have been described as
causative for canine hemophilia B.10-12,15,16 The identifica-
tion of a causative promoter variant in the Hovawart dogs
described here is therefore unique in two respects: it is the
first regulatory variant described in dogs and secondly this
variant resembles a specific subtype of hemophilia B,
known as hemophilia B Leyden, in humans.21 Hitherto, 21
distinct variants in the human F9 promoter have been
determined in families affected by hemophilia B Leyden.48
These variants cluster in the so-called Leyden-specific
region (LSR) and interfere with the binding of different
transcription factors, e.g. AR, HNF4α, ONECUT, and
C/EBPα.49 The deletion identified in the Hovawart dogs
was located 73 bp upstream of the start codon of the
canine F9 gene corresponding to position -23 in the third
human promoter cluster harboring the overlapping bind-
ing sites of AR and HNF4α.48 Similar to analyses in
humans, it was possible to show by electrophoretic
mobility shift assay that the deletion in the canine pro-
moter abolished HNF4α binding because it affects the
highly conserved core sequence of the HNF4α binding
motif.24 On the other hand, binding of AR was not affect-
ed. This might be due to the fact that AR DNA-binding
Christmas disease in a Hovawart family
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Figure 3. Dual-luciferase reporter analysis of F9 promoter activities in Hep G2
cells. Box and whisker plot showing the change of relative response ratios (RRR)
between the wildtype (F9-wt) and mutant promoter (F9-mut) gene constructs.
The lines in the boxes represent the medians. Whiskers indicate minimum and
maximum RRR values. Values were normalized as described in the Online
Supplementary Methods. P-values are indicated.
Figure 2. Analysis of hepatocyte nuclear factor 4α and androgen receptor binding of wildtype and mutated F9 promoter regions using an electrophoretic mobility
shift assay. (A, B) Human hepatocyte nuclear factor 4α (HNF4α) and (B) androgen receptor (AR) were used to bind biotin-labeled wildtype and mutated F9 promoter
fragments (F9-wt, F9-mut). Specific shifted bands (solid arrowheads) are detected in lane 2 (A) for HNF4α and lanes 5 and 6 (B) for AR. To test specificity, binding
reactions were also performed using bovine serum albumin [BSA; lanes 3 and 4 (A), lanes 1 and 2 (B)]. In lanes 5 and 6 (A) and lanes 3 and 4 (B) no protein was
added. Binding reactions were separated on 12% Tris-Glycine gels. X-ray films were cropped using GIMP 2.8.22. The 70 kDa protein marker band (PageRuler
Prestained Protein Ladder, Fermentas) is indicated with an asterisk (lane M). The open arrowhead indicates unbound, free DNA.
A B
sites display an exceptional amount of sequence
variation.50 Although the C-deletion is located in the con-
sensus TGTNCT-motif of class I AR-binding sites several
alternative motives, e.g. TGTTTC in the stomatin-like
protein 3 gene or TGTATC in the prostate-specific antigen
gene enhancer III region, have been reported.50-52
Therefore, it can be assumed that the affected males
would have recovered from hemophilia during puberty.
To what extent a sex- or possibly also age-dependent ame-
lioration of the hemophilia B Leyden, as described in
humans and also a mouse model, might be present in the
affected Hovawarts remains to be determined.49,53 In this
respect the Hovawart family could also be of interest as a
model in the comparative analysis of age-dependent nor-
malization of F9 expression in symptomatic carriers of
hemophilia B Leyden in humans.
To analyze whether the deletion not only affected
HNF4α binding but also resulted in a downregulation of
F9 expression, we performed luciferase assays. Although
relative response ratios do not directly reflect F9mRNA or
FIX levels in vivo, silencing of the promoter activity due to
the deletion was obvious from these experiments. Similar
findings have been made using HNF4α-null mice.26 In the
murine model it was shown that expression of factors V,
XI, XII, and XIIIB directly depends on hepatic HNF4α.
Northern blot analysis also demonstrated that F9 expres-
sion was decreased with a significantly prolonged aPTT in
the HNF4α-null mice.26 The finding that F9 expression
was not completely dependent on HNF4α is in agreement
with the observation that control of F9 transcription in
mice and humans is complex and depends on a plethora of
factors.26 For instance, in earlier studies it was shown,
using DNaseI footprinting, that there are further binding
sites of HNF4α and other factors, e.g. ARP1, COUP/Ear3,
in the human F9 promoter influencing F9 expression.54
However, the classical HNF4α binding site at position -26
to -19 only binds HNF4α. When analyzing the canine F9
promoter using transcription factor binding site prediction
algorithms, further potential binding motifs for HNF4α
and other transcription factors were predicted (data not
shown).55-57 As ectopic expression of F9 in vivo can be
excluded or at least ignored according to recent RNA-
sequencing analyses,58 a remaining reduced hepatic activi-
ty of the mutated promoter is in agreement with the clin-
ical findings of residual FIX activity in the affected males
(Online Supplementary Table S1) and the results of the elec-
trophoretic mobility shift assay showing binding of AR in
androgen-dependent promoter activation.
In summary, we have identified and elucidated the
causative genetic variant for hemophilia B Leyden in
Hovawarts. This is the first report on a single nucleotide
deletion within the binding sites of HNF4α and AR in the
F9 promoter causing hemophilia B Leyden in dogs. As the
deletion only abolishes the binding of HNF4α, it can be
assumed that male dogs will most likely recover during
puberty, as reported in humans.30,59,60 However, to prevent
any risk of a further propagation of the disorder, genotyp-
ing of females is recommended in further breeding.
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